Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Obesity Right
  3. Zepbound (tirzepatide) injection Right
  4. Can people with gallbladder disease or gallbladder removal take Zepbound® (tirzepatide)?
Search Zepbound (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Zepbound ® (tirzepatide) injection

2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Can people with gallbladder disease or gallbladder removal take Zepbound® (tirzepatide)?

Lilly cannot provide treatment recommendations on the use of tirzepatide in people with a history of gallbladder disease or removal. These participants were not excluded from tirzepatide trials, but no subgroup analysis was completed in this population.

US_cFAQ_TZPCWM348_USE_IN_PEOPLE_WITH_GALLBLADDER_DISEASE
US_cFAQ_TZPCWM348_USE_IN_PEOPLE_WITH_GALLBLADDER_DISEASEen-US

See important safety information, including boxed warning, in the attached prescribing information.

Tirzepatide Use in Patients With Gallbladder Disease or Prior Gallbladder Removal

The use of tirzepatide in people with gallbladder disease or prior gallbladder removal is not listed as a contraindication.1

Participants with gallbladder disease or prior gallbladder removal were not explicitly excluded from the tirzepatide clinical trial programs for weight management.2-5

Eli Lilly and Company has not sponsored a subgroup analysis in participants with a preexisting condition of gallbladder disease or prior gallbladder removal in the tirzepatide weight management clinical studies.

Clinical Considerations

Treatment with tirzepatide and GLP-1 receptor agonists is associated with an increased occurrence of acute gallbladder disease.1

In a pool of 2 tirzepatide weight management clinical trials (SURMOUNT-1 and SURMOUNT-2),

  • cholelithiasis was reported in 1.1% of tirzepatide-treated patients and 1% of placebo-treated patients
  • cholecystitis was reported in 0.7% of tirzepatide-treated patients and 0.2% of placebo-treated patients, and
  • cholecystectomy was reported in 0.2% of tirzepatide-treated patients and no placebo-treated patients.1

Acute gallbladder events were associated with weight reduction. If cholecystitis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.1

Eli Lilly and Company cannot provide treatment recommendations on the use of tirzepatide in people who have a history of gallbladder disease or prior gallbladder removal. In formulating an assessment and approach, the health care practitioner may consider

  • the information provided
  • the patient’s prior medical history and concomitant medications, and
  • other individual factors.

The health care professional should consider potential risks and benefits of tirzepatide use in these patients

Enclosed Prescribing Information

ZEPBOUND® (tirzepatide) injection, for subcutaneous use, Lilly

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.

2Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038

3Garvey WT, Frias JP, Jastreboff AM, et al; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. https://doi.org/10.1016/S0140-6736(23)01200-X

4Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909-2918. https://doi.org/10.1038/s41591-023-02597-w

5Aronne LJ, Sattar N, Horn DB, et al; SURMOUNT-4 Investigators. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. https://doi.org/10.1001/jama.2023.24945

Date of Last Review: January 28, 2025

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.44 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly